Aviva PLC Sells 36,633 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Aviva PLC trimmed its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 35.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,346 shares of the company's stock after selling 36,633 shares during the period. Aviva PLC's holdings in MiMedx Group were worth $629,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of MDXG. Trexquant Investment LP raised its holdings in shares of MiMedx Group by 29.7% during the 4th quarter. Trexquant Investment LP now owns 221,262 shares of the company's stock worth $2,129,000 after acquiring an additional 50,635 shares in the last quarter. Wellington Management Group LLP increased its position in MiMedx Group by 22.8% in the fourth quarter. Wellington Management Group LLP now owns 389,706 shares of the company's stock worth $3,749,000 after purchasing an additional 72,432 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after purchasing an additional 300,433 shares during the last quarter. Norges Bank purchased a new position in shares of MiMedx Group in the 4th quarter worth $4,020,000. Finally, JPMorgan Chase & Co. grew its stake in shares of MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after buying an additional 395,739 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Insider Transactions at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on MDXG shares. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Friday, April 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Trading Down 0.8 %

MiMedx Group stock traded down $0.06 during midday trading on Wednesday, reaching $6.75. The stock had a trading volume of 64,493 shares, compared to its average volume of 693,679. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $993.98 million, a price-to-earnings ratio of 12.27 and a beta of 1.74. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a fifty day moving average of $7.79 and a 200 day moving average of $8.00.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. On average, analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.